IMP21052

IMP21052 is an experimental small molecule oxime reactivator developed by the French Armed Forces Health Service (Direction Centrale du Service de Santé des Armées - DCSSA) and the Institut de Recherche Biomédicale des Armées (IRBA). It is specifically designed as a medical countermeasure for poisoning caused by organophosphorus (OP) compounds, which include chemical warfare nerve agents (such as sarin, soman, and VX) and certain organophosphate pesticides. The drug's primary mechanism of action is the reactivation of acetylcholinesterase (AChE) that has been inhibited (phosphonylated or phosphorylated) by the OP agent. By dephosphonylating the enzyme's active site, IMP21052 restores the ability of AChE to hydrolyze acetylcholine, thereby mitigating the life-threatening cholinergic crisis associated with OP exposure. Research has focused on its potential for improved central nervous system penetration and broader efficacy against various nerve agents compared to traditional oximes like pralidoxime or obidoxime.